Zoetis (NYSE:ZTS) Announces Retirement of R&D President, Appoints Successor

November 3, 2025 — Leads & Copy —

Zoetis Inc. (NYSE: ZTS) announced that Rob Polzer, Ph.D., Executive Vice President and President, Research and Development, will retire at the end of 2025 after a 10-year career. Kevin Esch, D.V.M, M.P.H., Ph.D., Dipl. ACVP (anatomic), currently Senior Vice President of Global Therapeutics, will succeed Dr. Polzer effective January 1, 2026.

Dr. Polzer will retire from Zoetis on February 28, 2026, and will be available as a scientific advisor through 2026. Zoetis will host an Innovation Webcast on Tuesday, December 2 at 8:30 a.m. ET to update investors on its innovative pipeline.

Kristin Peck, Chief Executive Officer, Zoetis, expressed gratitude for Polzer’s contributions and confidence in Esch’s leadership.

About Zoetis: Zoetis is the world’s leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals.

Contact:
Media
Bill Price
973-443-2742 (o)
908-229-0319 (m)
bill.price@zoetis.com

Source: Zoetis

×

Welcome!

BiotechReporter.news is a Leads & Copy Publication

Leads & Copy is a Media “news tip” source, providing Industry Reporters story Leads, written as Publishable CP-style Copy.

By Subscribing you will receive Daily Biotech Story Leads via email 10:30 am Mon-Fri.